“The Starpax project fits perfectly into the overall strategy of the CIUSSS du Centre-Ouest de Montréal to place increasing emphasis on the use and active development of new forms of technology to meet the needs of patients” , said Dr. Lawrence Rosenberg, President and CEO of the CIUSSS. “With the help of the government and our partners, we intend to apply all our world-renowned expertise to reduce the burden of cancer and its treatment.”
Starpax Biopharma Inc. has developed a novel 3D precision magnetodrone guidance therapy in tumors. Magnetodrones are unique drug-carrying bacteria developed by Starpax that are sensitive to magnetic fields. They deliver the drug into the tumor mass, without allowing the drug to travel through the bloodstream. At the same time, magnetodrones saturate hypoxic areas where cancer cells are difficult to reach with other treatments. The magnetodrones are injected directly into the tumor and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak prevents the magnetdrones from leaving the tumor and guides them in 3D with special magnetic fields.
“Starpax is thrilled to unveil this world first, the invention of precision magnetodrone guidance therapy with the PolarTrak,” said Michael Gareau, Founding President of Starpax Biopharma. “This unprecedented multidisciplinary technology, with preclinical results demonstrating a 100% remission rate with no observed side effects, brings together 31 inventions in four scientific disciplines, including microbiology, biochemistry, electromagnetics and artificial intelligence. It propels cancer medicine into the future. “
“We are committed to bringing this innovation to our patients here, but also eventually to patients around the world,” notes Dr. Gerald Batiste, oncologist and director of the Segal Cancer Center at the JGH. “Such an approach has enormous potential and could help us better treat many types of cancer. Innovation requires building bridges and then crossing them, as well as sharing knowledge, resources and vision to create new hope and better results.
This new approach has the potential to reduce the toxicity of treatments compared to current systemic use, resulting in long-term cost savings to the healthcare system.
The Ministry of Economy and Innovation has granted funding of up to $7 million to set up the PolarTrak room. This financing will cover 80% of the cost of renovating and equipping the hall. The JGH Foundation contributed 20% of the funding for this project.
“If we want to have an efficient and effective health system, we must equip our specialists with state-of-the-art equipment,” said Peter Fitzgibbon, Minister of Economy and Innovation and Minister responsible for Regional Economic Development. “This new room at the Jewish General Hospital will make it possible to innovate with cutting-edge treatments, in addition to creating direct spinoffs from the dynamism of research in Quebec. This is exactly the type of project that makes our science industry shine here and around the world.”
The first clinical studies in humans will focus on six types of cancer: metastases to the pancreas, prostate, head and neck, rectum, vulva and skin, including recurrence of breast cancer.
“Polytechnique is proud to have been at the genesis of the scientific advances that led to the development of this very promising new way to treat cancer,” said Gilles Savard, interim director general of Polytechnique Montréal. “This is a fine example of university research, where multiple collaborations, including those of Starpax and the Jewish General Hospital, are paving the way for applications that have a direct and positive impact on society.
The first human clinical trials are expected to begin in late 2022 or early 2023.
SOURCE Starpax Biopharma
Information: For more details and interview requests: For the CIUSSS: [email protected]; For Starpax: [email protected]; For Minister Fitzgibbon: [email protected]